Daily Ards Research Analysis

BACKGROUND: Acute respiratory distress syndrome (ARDS) is characterized by increased alveolar-capillary permeability and neutrophil-driven inflammation. Anumigilimab, a novel, fully human, monoclonal antibody, competitively antagonizes the granulocyte colony-stimulating factor (G-CSF) receptor. This trial aimed to assess its potential in modulating pulmonary inflammation induced by segmental lipopolysaccharide (LPS) challenge. METHODS: In this randomized, double-blind, placebo-controlled Phase 1b trial (NCT05653713), healthy adults were randomized 1:1 to receive a single intravenous dose of anumigilimab 0.6 mg/kg or placebo (0.9% saline), followed by LPS challenge on Day 3. Biomarkers were measured in bronchoalveolar lavage (BAL) and blood before and after LPS challenge. The primary endpoint was the percentage reduction from baseline in mean absolute neutrophil cell count in BAL following LPS challenge. Secondary endpoints included additional BAL biomarkers of neutrophilic inflammation and tissue injury. Pharmacokinetics, pharmacodynamics, and safety were also assessed. RESULTS: Participants were randomly assigned to anumigilimab (n = 23) or placebo (n = 22). LPS challenge induced expected increases in BAL neutrophils and inflammatory biomarkers, with no significant difference between groups. Target engagement was confirmed by elevated plasma and BAL G-CSF concentrations and transient reductions in peripheral neutrophil counts following anumigilimab administration. Pharmacokinetic/pharmacodynamic parameters were consistent with prior clinical data. Anumigilimab was well tolerated; mild transient neutropenia occurred in four participants treated, with no serious adverse events. CONCLUSIONS: While anumigilimab had an acceptable safety profile in healthy volunteers, and favorable pharmacokinetic/pharmacodynamic characteristics, it did not attenuate LPS-induced neutrophilic inflammation. Further preclinical investigations are warranted before advancing its clinical development in ARDS.

Lung-protective ventilation is the current standard for mechanical ventilation of patients with acute respiratory distress syndrome (ARDS). Traditionally, this approach has focused on the controlled phase of mechanical ventilation, but emerging data suggest that how patients are managed during assisted ventilation may also impact clinical outcomes. Experimental and observational clinical data indicate that excessive respiratory effort may further damage already injured lungs and may also lead to diaphragm myotrauma. Conversely, insufficient effort and prolonged passive ventilation are associated with diaphragm atrophy and dysfunction. Recent non-invasive techniques to monitor respiratory drive and effort at the bedside have facilitated the development of a new strategy to protect both the lungs and the diaphragm. The lung- and diaphragm-protective (LDP) ventilation framework highlights the need to better integrate ventilation and sedation strategies to facilitate timely and safe spontaneous breathing. This new paradigm has driven the development of emerging supportive and therapeutic modalities, such as diaphragm neurostimulation and partial neuromuscular blockade. Clinical trials are needed to evaluate the impact of LDP strategies on patient-centered outcomes, using designs that account for the possibility of heterogeneity of treatment effect in the ARDS population. In this review, we summarize the physiological background for the LDP framework, as well as the current clinical evidence evaluating this strategy.

Critical care has produced hundreds of neutral randomized trials, in part because therapies have been tested in biologically incoherent populations that dilute meaningful treatment effects. Syndromic diagnoses such as sepsis, acute respiratory distress syndrome, and traumatic brain injury group distinct pathobiological states under a single label, limiting the ability to detect treatment-responsive subgroups. While high-dimensional omics technologies have revealed this biologic heterogeneity, the field lacks a practical framework to translate these insights into clinical trial design and bedside decision-making. This Review addresses the translational gap in precision critical care through a pathway-level framework. We synthesize advances in genomics, transcriptomics, proteomics, and metabolomics, highlighting their roles in capturing susceptibility, host response, effector function, and real-time physiology. We propose pathway-focused biomarkers as clinically translatable signatures that preserve biological mechanisms while enabling practical measurement. We outline how pathway enrichment, network analysis, and multi-omic integration can identify these programs, and how feature selection can derive parsimonious biomarker panels for clinical use. This approach also supports pathway-guided drug repurposing by linking dysregulated molecular programs to existing therapies. Together, these signatures provide a framework for predictive enrichment, aligning patient selection with therapeutic mechanisms and facilitating implementation within adaptive platform trials. This Review serves as a practical primer that outlines the concepts and methods needed to translate omics into clinically actionable tools. By shifting from syndromic classification to pathway-defined biology, it provides a framework for biomarker development, trial design, and precision critical care.